Non-profit asks US government to take Gilead hepatitis C patent

A non-profit organisation has requested that the US government take the title of a patent covering Gilead’s sofosbuvir-based hepatitis C medicine.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Asia

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Americas

Kite and Gadeta team up in cancer fight

23 July 2018 Biopharmaceutical company Kite, a subsidiary of Gilead, and immunotherapy development company Gadeta announced on Thursday, July 19 that they have entered into a strategic collaboration to produce cancer therapies.

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Asia

MSF challenges Gilead patent application in China

Americas

Kite and Gadeta team up in cancer fight

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Asia

MSF challenges Gilead patent application in China

Americas

Kite and Gadeta team up in cancer fight